The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma

Publication date: 1 August 2017
Source:Cancer Letters, Volume 400
Author(s): Hiroaki Miyahara, Sridevi Yadavilli, Manabu Natsumeda, Jeffrey A. Rubens, Louis Rodgers, Madhuri Kambhampati, Isabella C. Taylor, Harpreet Kaur, Laura Asnaghi, Charles G. Eberhart, Katherine E. Warren, Javad Nazarian, Eric H. Raabe
Diffuse intrinsic pontine glioma (DIPG) is an invasive and treatment-refractory pediatric brain tumor. Primary DIPG tumors harbor a number of mutations including alterations in PTEN, AKT, and PI3K and exhibit activation of mammalian Target of Rapamycin Complex 1 and 2 (mTORC1/2). mTORC1/2 regulate protein translation, cell growth, survival, invasion, and metabolism. Pharmacological inhibition of mTORC1 is minimally effective in DIPG. However, the activity of dual TORC kinase inhibitors has not been examined in this tumor type.Nanomolar levels of the mTORC1/2 inhibitor TAK228 reduced expression of p-AKT^S473 and p-S6^S240/244 and suppressed the growth of DIPG lines JHH-DIPG1, SF7761, and SU-DIPG-XIII. TAK228 induced apoptosis in DIPG cells and cooperated with radiation to further block proliferation and enhance apoptosis.TAK228 monotherapy inhibited the tumorigenicity of a murine orthotopic model of DIPG, more than doubling median survival (p = 0.0017) versus vehicle. We conclude that dual mTOR inhibition is a promising potential candidate for DIPG treatment.



from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2q5wA8j
via IFTTT